|
US6177443B1
(en)
|
1997-03-07 |
2001-01-23 |
Novo Nordisk A/S |
4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
|
|
UA74826C2
(en)
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
US6720330B2
(en)
|
2000-11-17 |
2004-04-13 |
Pfizer Inc. |
Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
|
|
JP2005508968A
(ja)
|
2001-10-19 |
2005-04-07 |
トランス テック ファーマ，インコーポレイテッド |
ＰＴＰ阻害剤としてのβ−カルボリン誘導体
|
|
US7767689B2
(en)
|
2004-03-15 |
2010-08-03 |
Ptc Therapeutics, Inc. |
Carboline derivatives useful in the treatment of cancer
|
|
US8076352B2
(en)
|
2004-03-15 |
2011-12-13 |
Ptc Therapeutics, Inc. |
Administration of carboline derivatives useful in the treatment of cancer and other diseases
|
|
UA92317C2
(ru)
|
2004-03-15 |
2010-10-25 |
Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. |
Производные карболина, пригодные для ингибирования развития кровеносных сосудов
|
|
WO2006058088A2
(en)
|
2004-11-23 |
2006-06-01 |
Ptc Therapeutics, Inc. |
Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
|
|
EP1829874B1
(en)
|
2004-12-22 |
2014-02-12 |
Ono Pharmaceutical Co., Ltd. |
Tricyclic compound and use thereof
|
|
WO2007002051A1
(en)
|
2005-06-22 |
2007-01-04 |
Smithkline Beecham Corporation |
Carboline derivatives and their use as inhibitors of flaviviridae infections
|
|
WO2008002490A2
(en)
|
2006-06-23 |
2008-01-03 |
Radius Health, Inc. |
Treatment of vasomotor symptoms with selective estrogen receptor modulators
|
|
US20100158858A1
(en)
|
2007-04-13 |
2010-06-24 |
Liangxian Cao |
Administration of carboline derivatives useful in the treatment of cancer and other diseases
|
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
WO2010107485A1
(en)
|
2009-03-17 |
2010-09-23 |
The Trustees Of Columbia University In The City Of New York |
E3 ligase inhibitors
|
|
WO2010138685A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating prostate conditions
|
|
US20120202801A1
(en)
|
2009-05-27 |
2012-08-09 |
Liangxian Cao |
Methods for treating breast cancer
|
|
MX373926B
(es)
|
2009-05-27 |
2020-07-10 |
Ptc Therapeutics Inc |
Metodos para tratar cancer y estados no neoplasicos.
|
|
WO2010138695A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating neurofibromatosis
|
|
WO2010138659A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating brain tumors
|
|
WO2010138652A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating kaposi sarcoma
|
|
WO2011103487A1
(en)
|
2010-02-18 |
2011-08-25 |
Medivation Technologies, Inc. |
Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
|
|
WO2011150162A1
(en)
|
2010-05-27 |
2011-12-01 |
Ptc Therapeutics, Inc. |
Methods for treating viral conditions
|
|
RS56042B1
(sr)
|
2010-06-10 |
2017-09-29 |
Seragon Pharmaceuticals Inc |
Modulatori estrogenih receptora i njihove upotrebe
|
|
WO2013090829A1
(en)
|
2011-12-14 |
2013-06-20 |
Aragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
US9499538B2
(en)
|
2012-03-20 |
2016-11-22 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
ES2671516T3
(es)
|
2013-02-19 |
2018-06-06 |
Novartis Ag |
Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
|
|
MX2015011132A
(es)
|
2013-03-14 |
2015-11-30 |
Seragon Pharmaceuticals Inc |
Moduladores policiclicos del receptor de estrogenos y sus usos.
|
|
UY35590A
(es)
*
|
2013-05-28 |
2014-11-28 |
Astrazeneca Ab |
Nuevos compuestos para el tratamiento del cáncer
|
|
EP3089747A1
(en)
|
2013-12-06 |
2016-11-09 |
F. Hoffmann-La Roche AG |
Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
|
|
MX388871B
(es)
|
2014-06-27 |
2025-03-20 |
Nogra Pharma Ltd |
Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
|
|
WO2016069949A1
(en)
|
2014-10-29 |
2016-05-06 |
Virginia Tech Intellectual Properties, Inc. |
Compositions and formulations of methylerthritol phosphate pathway inhibitors and uses thereof
|
|
TWI874834B
(zh)
*
|
2014-12-18 |
2025-03-01 |
瑞士商赫孚孟拉羅股份公司 |
四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
|
|
KR20240142622A
(ko)
|
2015-10-01 |
2024-09-30 |
올레마 파마슈티컬스 인코포레이티드 |
테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
|
|
KR20220071293A
(ko)
*
|
2016-04-01 |
2022-05-31 |
리커리엄 아이피 홀딩스, 엘엘씨 |
에스트로겐 수용체 조절제
|
|
EP3472162B1
(en)
|
2016-06-16 |
2021-11-17 |
F. Hoffmann-La Roche AG |
Heteroaryl estrogen receptor modulators and uses thereof
|
|
WO2018130123A1
(zh)
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的五环类化合物及其应用
|
|
WO2018130124A1
(zh)
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的三环类化合物及其应用
|
|
AU2018347307A1
(en)
|
2017-10-09 |
2020-04-23 |
Nuvation Bio Inc. |
Heterocyclic compounds and uses thereof
|
|
CN109867659A
(zh)
|
2017-12-04 |
2019-06-11 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物的制备方法
|
|
CN111601797B
(zh)
|
2018-05-23 |
2022-11-22 |
江苏恒瑞医药股份有限公司 |
苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
|
|
CR20200621A
(es)
*
|
2018-06-21 |
2021-02-03 |
Hoffmann La Roche |
Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
|
|
JP7571006B2
(ja)
|
2018-08-17 |
2024-10-22 |
ジェネンテック， インコーポレイテッド |
乳がんの処置のための診断的および治療的方法
|
|
KR20220044528A
(ko)
|
2019-08-06 |
2022-04-08 |
리커리엄 아이피 홀딩스, 엘엘씨 |
돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
|
|
AU2020380211A1
(en)
|
2019-11-04 |
2022-05-19 |
Recurium Ip Holdings, Llc |
Salts and forms of an estrogen receptor modulator
|
|
WO2021216671A1
(en)
|
2020-04-22 |
2021-10-28 |
Recurium Ip Holdings, Llc |
Preparation of an selective estrogen receptor degrader
|
|
EP4267578A4
(en)
*
|
2020-12-23 |
2024-11-20 |
Recurium IP Holdings, LLC |
ESTROGEN RECEPTOR MODULATORS
|